The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MEDIF | -1.26% | -91.5% | -38.92% | -97% |
| S&P | +14.5% | +93.32% | +14.09% | +132% |
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company focuses on the downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. It supplies raw materials, formulations, processing, and packaging for the creation of ready-to-sell derivative products. The company was founded by Patrick McCutcheon in 2015 and is headquartered in Barrie, Canada.
Despite a recent rough patch, the marijuana industry should deliver exciting sales growth next year.
A steep fall in demand and the economic ravages of the coronavirus badly affected the company's business.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $8.53M | 12.8% |
| Gross Profit | $2.34M | -10.8% |
| Gross Margin | 27.41% | -7.3% |
| Market Cap | $20.76M | -6.9% |
| Market Cap / Employee | $0.13M | 0.0% |
| Employees | 161 | -3.0% |
| Net Income | -$2.72M | -44.3% |
| EBITDA | -$2.57M | -114.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.59M | -35.0% |
| Accounts Receivable | $5.16M | 20.3% |
| Inventory | 6.9 | -2.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.01M | -78.7% |
| Short Term Debt | $0.39M | -80.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -15.68% | 4.4% |
| Return On Invested Capital | -48.55% | -5.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.09M | -83.7% |
| Operating Free Cash Flow | -$2.05M | -87.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.59 | 0.51 | 0.93 | 0.69 | 14.37% |
| Price to Sales | 0.69 | 0.57 | 0.93 | 0.67 | -16.03% |
| Price to Tangible Book Value | 0.60 | 0.52 | 0.95 | 0.70 | 14.23% |
| Enterprise Value to EBITDA | -9.98 | -8.49 | -134.52 | -5.50 | -47.54% |
| Return on Equity | -23.7% | -22.3% | -16.2% | -19.6% | -22.05% |
| Total Debt | $0.48M | $0.27M | $0.09M | $0.40M | -80.66% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
